 NEEDHAM, Mass., Nov. 01, 2022 GLOBE NEWSWIRE -- Candel Therapeutics, Inc. Nasdaq: CADL, a clinical stage biopharmaceutical company developing novel viral immunotherapies, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in the following investor conferences in November: 